Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPA-BP: Empagliflozin vs Metformin for Blood Pressure in T2DM
NCT07541456Phase 4Completed
- Sponsor
- Dr. Zarmina Younes
- Start
- Jun 2025
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of empagliflozin in type 2 diabetes mellitus (T2DM) and hypertension (HTN) (2 arms), sponsored by Dr. Zarmina Younes. Primary endpoint: Change in Systolic Blood Pressure at 12 weeks. Started Jun 2025; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)hypertension (HTN)
Beyond the preview
Go deeper on NCT07541456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07541456.